CURA_1170x120_8-22-19

Biotechnology Industry Organization

N.J. governor signs biosimilars legislation

N.J. governor signs biosimilars legislation

WASHINGTON — New Jersey Gov. Chris Christie has approved legislation to create a pathway for the substitution of interchangeable biologic drugs, drawing praise from the Biotechnology Industry Organization (BIO) and BioNJ, a state biotechnology organization. Christie signed Assembly Bill 2477 into law on Monday, following unanimous passage in the New Jersey Senate and Assembly earlier

California gives green light to substitution of biologics

California gives green light to substitution of biologics

WASHINGTON — California Gov. Jerry Brown has approved legislation to create a pathway for the substitution of interchangeable biologic drugs, a move applauded by Biotechnology Industry Organization (BIO). This week, Brown signed Senate Bill 671 into law, following recent passage in both the California Senate and Assembly. The legislation authorizes a pharmacist filling a prescription

State biosimilars legislation hailed by GPhA

WASHINGTON — The Generic Pharmaceutical Association (GPhA) and its recently formed Biosimilars Council have praised the enactment of new legislation in five states to allow automatic substitution for Food and Drug Administration-approved interchangeable biologic products. Bills in Colorado (SB 71), Georgia (SB 51), Tennessee (SB 984), Utah (HB 279) and Washington (SB 5935) reflect core